Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniela Marschall-Kehrel.
Journal of the American Geriatrics Society | 2013
Adrian Wagg; Vik Khullar; Daniela Marschall-Kehrel; Martin C. Michel; Matthias Oelke; Amanda Darekar; Caty Ebel Bitoun; David Weinstein; Ian Osterloh
To assess the efficacy and safety of flexible‐dose fesoterodine in elderly adults with overactive bladder (OAB).
World Journal of Urology | 2014
Matthias Oelke; Daniela Marschall-Kehrel; Thomas R. W. Herrmann; Richard Berges
This editorial of the topic issue of the World Journal of Urology provides a state of the art on nocturia which includes descriptions of the terminology, epidemiology, health-related quality of life, medical and financial consequences, pathophysiology, assessment tools and treatment strategies of nocturia. This summary also includes a flowchart on the pathophysiology of nocturia with illustration of the various causes of reduced bladder capacity, increased fluid intake or increased diuresis; a flowchart with the key findings of frequency–volume charts to determine the underlying pathophysiology; and a flowchart on the treatment of the various causes of nocturia. The editorial critically discusses current assessment and treatment strategies in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and nocturia. The outcome of nocturia remains hidden in drug trials of patients with LUTS/BPH because nocturia-specific measures were not included. The authors recommend using frequency–volume charts, measurement of the hours of undisturbed sleep, and nocturia-specific quality of life questionnaires (e.g., ICIQ-N or N-Qol) in all future studies in patients with LUTS/BPH and nocturia.
British Journal of Clinical Pharmacology | 2012
Martin C. Michel; Piotr Radziszewski; Christian Falconer; Daniela Marschall-Kehrel; Koenraad Blot
AIMS To determine efficacy of the analgesic flupirtine in the treatment of overactive bladder syndrome in a proof-of-concept study. METHODS Double-blind, double-dummy, three-armed comparison of flupirtine extended release (400 mg/day, titrated to 600 mg/day), tolterodine extended release (4 mg/day) and placebo for 12 weeks. RESULTS When major elevations of liver enzymes (more than three times the upper normal limit) were detected in several flupirtine-exposed patients, the study was prematurely discontinued. Based on study-end data, hepatotoxicity was detected in 31% of patients receiving flupirtine for ≥ 6 weeks. CONCLUSIONS Unexpected frequent and relevant toxicity can occur when testing an established drug for a new indication.
International Urogynecology Journal | 2013
Vik Khullar; Daniela Marschall-Kehrel; Montserrat Espuña-Pons; Con Kelleher; Shannon Elizabeth Tully; Elisabeth Piault; Linda Brubaker; Aino Fianu-Jonasson; David Weinstein; Agneta Bergqvist; Marion Kvasz
Introduction and hypothesisThe Self-Assessment Goal Achievement (SAGA) questionnaire is a patient-completed instrument designed to assess goal attainment in the behavioral or pharmacologic treatment of lower urinary tract symptoms (LUTS), including overactive bladder (OAB). The SAGA questionnaire allows patients to identify and rank the importance of treatment goals before treatment is initiated; the follow-up SAGA questionnaire quantifies the achievement of these patient-identified goals. The objective of this qualitative research was to confirm the content validity of the German, Spanish, Swedish, and English (UK) language versions of the SAGA questionnaire in patients with OAB with or without other LUTS.MethodsThe SAGA questionnaire was translated to each language in accordance with a well-established forward and backward harmonization method. Patient interviews were then conducted according to a cognitive debriefing methodology. Qualitative analysis of patients’ input allowed assessment of content validity of each linguistically adapted SAGA questionnaire.ResultsAll patients (n = 29; six to eight per targeted country) found the SAGA questionnaire easy to understand and to complete. Most patients completed the nine prespecified (fixed) treatment goals and were able to add up to five personal goals in the open-ended portion and rate each goal by importance. Differences were identified in how the various languages communicated some of the concepts assessed with the SAGA questionnaire. Rewording of the translated versions of the questionnaire was necessary in some cases.ConclusionsThis linguistic content validation study in four European languages indicates that SAGA is a comprehensive, easy-to-understand, and relevant questionnaire for patient-completed evaluation of LUTS/OAB symptoms and treatment goal attainment.
Urology | 2004
Daniela Marschall-Kehrel
Neurourology and Urodynamics | 2014
Vik Khullar; Monserrat Espuna‐Pons; Daniela Marschall-Kehrel; Aino Fianu-Jonasson; Con Kelleher; Linda Brubaker; James Beach; Elisabeth Piault; Jeffrey Trocio
European Urology Supplements | 2011
Adrian Wagg; Vik Khullar; Daniela Marschall-Kehrel; Martin C. Michel; Matthias Oelke; D.G. Tincello; Amanda Darekar; C. Ebel Bitoun; Ian Osterloh; David Weinstein
ics.org | 2008
Martin C. Michel; Piotr Radziszewski; Christian Falconer; Daniela Marschall-Kehrel; Chris Rundfeldt; Frederic Vanhoutte
European Urology Supplements | 2012
Adrian Wagg; Vik Khullar; Matthias Oelke; Daniela Marschall-Kehrel; Martin C. Michel; Amanda Darekar; C. Ebel-Bitoun
ics.org | 2011
Adrian Wagg; Vik Khullar; Daniela Marschall-Kehrel; Martin C. Michel; Matthias Oelke; Amanda Darekar; Caty Ebel Bitoun; Ian Osterloh; David Weinstein